# TRANSCRIPT — R-STAT
model: gpt-5.5-2026-04-23 | reasoning_effort: high | retrieval: full-read | web: DISABLED (no hosted tools) | started: 2026-06-03T21:44:01
docs available: ['INDEX', 'proof', 'ref01', 'ref02', 'ref03', 'ref04', 'ref06', 'ref07', 'ref08', 'ref09', 'ref10', 'ref11', 'ref12', 'ref13', 'ref14', 'ref15', 'ref17', 'ref18', 'ref19', 'ref20', 'ref21', 'ref22', 'ref23', 'ref24']

===== DEVELOPER MESSAGE =====
You are running inside an OFFLINE evaluation harness. You have NO internet access and NO shell. Access documents ONLY through these tools:
- list_docs(): list available document names.
- search_doc(name, query): find passages matching a query (regex/text) with surrounding context.
- read_doc(name, offset, length): read a document, optionally a bounded window.
- write_note(name, content): optional scratch memory.
Documents: 'proof' (the submitted manuscript proof, including its bound supplementary appendix), 'INDEX' (maps each cited reference number to its source), and 'ref01'..'ref24' (full text of each cited reference). References 5 and 16 are NOT provided (no ref05/ref16). When the instructions refer to the manuscript PDF, 'pdfs/INDEX.md', or a reference's PDF, use the matching name (reference 7 -> 'ref07').

Read whatever you need (read_doc returns whole documents by default), then produce your review.

===== USER INSTRUCTION (verbatim) =====
You are serving as a peer reviewer for a general medical journal (the BMJ tier). You have been sent a manuscript reporting a randomized controlled trial and PDFs of the references it cites. You do not have the raw data or the analysis code — review what you have been given, as a reviewer at submission would. Your job is to produce a rigorous, fair, and specific peer-review report that helps the editors decide whether the work is sound and what revisions it needs.

You have no internet access. You are reviewing this manuscript pre-publication; treat the trial's results elsewhere, this paper, and any outside commentary as unavailable. The references the manuscript cites are provided as PDFs in `pdfs/` (an index maps each to its reference number) — consult those directly rather than relying on memory when you need to check what a cited source says.

Ground every point in the manuscript or a cited reference. Do not raise generic concerns you cannot tie to something specific in these materials. Distinguish issues that are major (could change conclusions or require new analysis) from minor (clarity, reporting). Be concrete: cite sections, tables, figures, page numbers, and the specific sentence at issue.

Produce your report in the format specified at the end of these instructions.

## Your role

Your focus is the statistical design and analysis as described in the manuscript: the primary outcome definition and its appropriateness; sample-size and power assumptions and whether the observed effect is consistent with them; the analysis model and whether it is correctly specified for the design (including stratification and clustering); confidence-interval construction; handling of missing data; multiplicity across secondary outcomes and subgroups; and whether the stated conclusions are supported by the estimates and their uncertainty. **The submission includes the trial protocol and statistical analysis plan — compare the analyses actually reported in the results against what was pre-specified there. Flag any departure from the pre-specified plan (changed or added outcomes, different model or adjustment set, unplanned subgroups, altered alpha-spending or significance threshold), any pre-specified analysis that is not reported, and anything presented as confirmatory that looks post hoc.** You do not have the data — scrutinize what the methods, results, protocol, and SAP report, and flag anything underspecified, internally inconsistent, or that would need the data to verify.

## Your materials

You have been given exactly these, and nothing else (no internet, no raw data, no analysis code, no published version of this paper, no other commentary):

1. **The submitted manuscript proof** — `inputs/27_jan_2026_bmj-2026-089636_proof_hi.pdf`. This is the complete submission. It **includes the supplementary appendix** bound at the end (table of contents plus supplementary tables S1–S14, the per-protocol population detail, supplementary figures, and a pointer to the trial's pre-specified protocol and statistical analysis plan). The pre-specified protocol itself is also provided as a cited reference (see below) — use both when comparing reported analyses against what was planned.
2. **The cited references** — the manuscript cites 24 references; their PDFs are in `pdfs/`, mapped reference-number → file in `pdfs/INDEX.md`. **22 of the 24 are present.** Two are unavailable: reference 5 and reference 16. For any point that would rest on one of those two sources, state that you could not check it because the source was not provided, rather than relying on memory.

## Required output format

End your review with these sections, in this order:

1. **Summary** (3–5 sentences: what the trial did, your overall assessment).
2. **Major points** (numbered; each with the specific manuscript/reference location).
3. **Minor points** (numbered).
4. **Anything you verified that checked out** (numbered; what you confirmed against a cited source — so editors know what was checked, not just what failed).
5. **Editorial recommendation** (accept / minor revision / major revision / reject) **with one paragraph of justification.**
6. **What I could not assess** (limits of what you could check with the materials given — e.g., anything needing the raw data).

===== FINAL OUTPUT =====
## 1. Summary

This multicentre, double blind, placebo controlled trial randomised women with placenta praevia undergoing caesarean delivery to tranexamic acid or placebo after cord clamping, with postpartum haemorrhage defined as calculated estimated blood loss ≥1000 mL or red cell transfusion within 2 days. The primary result favours tranexamic acid, but several aspects of the statistical reporting and protocol/SAP alignment need substantial clarification before the result can be interpreted with confidence. In particular, the timing and content of protocol/SAP amendments, post hoc PAS reclassification, analysis-model choices, and multiple internally inconsistent estimates in the tables require correction or explanation. The safety conclusion is also overstated given the very small number of serious adverse events and wide confidence intervals.

## 2. Major points

1. **Pre-specification is not adequately documented; several analysis-defining changes occurred after trial start and one after trial completion.**  
   - Manuscript Methods state that the authors attest to fidelity to “the protocol and statistical analysis plan” (Study design, p7, lines 176–180), but the bound protocol/SAP show important versioning issues. The first participant was enrolled on 7 Aug 2023 (protocol version history, p50), whereas the SAP is version 3.0 dated 1 Jun 2024 (SAP Section 1, p77), and the protocol is version 7.0 dated 16 Dec 2025 (protocol p49; SAP p77).  
   - SAP version 3.0 added or formalised the log-binomial mixed-effects model, the per-protocol definition, and the open-label tranexamic-acid sensitivity analysis (SAP revisions, pp81–82). The protocol version 7.0 states that, “in response to peer-review feedback,” PAS diagnoses were re-evaluated, changing PAS prevalence from 39.0% to 17.9% (protocol version history, p53).  
   - The cited protocol paper (ref12) was received 14 Feb 2025 and first published online 15 Jul 2025, after trial enrolment had begun and close to/after completion.  
   **Needed revision:** provide a clear chronology: dates of first enrolment, interim analysis, database lock, unblinding, each protocol/SAP version, and which analyses were finalised before any outcome data were reviewed. Do not describe analyses or classifications as “pre-specified” unless they were fixed before relevant outcome information was available.

2. **Eligibility/protocol discrepancy regarding ultrasound confirmation of placenta praevia.**  
   - The cited protocol specifies diagnosis of placenta previa “confirmed by ultrasound within one week before delivery” (ref12, Inclusion and exclusion criteria, p4).  
   - The manuscript instead states eligibility was based on “the last prenatal ultrasound” (Participants, p7, lines 182–188), and Table 1 shows 60/845 and 58/849 participants had the last ultrasound 1–2 weeks before delivery, with 2 placebo participants >2 weeks before delivery. Thus about 120/1694 randomised analysed participants did not meet the one-week criterion as written in ref12.  
   **Needed revision:** clarify whether the one-week ultrasound criterion was amended, when, and in which protocol version. If not amended prospectively, report this as a protocol deviation and provide a sensitivity analysis excluding these participants.

3. **Primary analysis model does not account for all randomisation stratification factors, and absolute effects are incompletely reported.**  
   - Randomisation was stratified by study site, maternal age group, and placenta praevia type (Randomisation and masking, p8, lines 206–210). The primary analysis used a log-binomial mixed-effects model with study centre as a random effect and “no covariates adjusted” (Statistical analysis, p10, lines 291–294; Figure 2 legend, p14, lines 431–432). Age group and placenta praevia type were not included, despite being stratification variables.  
   - The SAP also specified that binary outcomes would be presented with rate differences and 95% CIs (SAP Analysis methods, p90), but Table 2 reports relative risks only.  
   **Needed revision:** add a primary-outcome sensitivity analysis adjusted for all randomisation stratification factors, and report absolute risk differences with CIs for the primary and key secondary binary outcomes. If the authors believe the current model is preferable, justify the omission of age group and placenta type.

4. **Several table estimates are mathematically inconsistent with the displayed counts, raising concern about analysis or transcription errors.**  
   Examples:  
   - Table 2, “Transfusion by discharge”: 164/845 vs 185/849 implies a crude RR ≈0.89, not 0.85, and the reported CI 0.85 to 0.86 is implausibly narrow for these counts.  
   - Table 2, “Transfer to intensive care unit”: 113/845 vs 115/849 implies RR ≈0.99, not 1.03, and the CI 0.98 to 1.08 is also implausibly narrow for 228 events.  
   - Table 2, “Gravimetrically estimated blood loss”: means 790 vs 813 mL imply a difference of about −23 mL; the reported CI “−41.30 to 90.70” is not centred on the estimate and appears to have a sign/order error.  
   - Table S11, per-protocol population: “Uterotonic agent other than oxytocin” is 774/831 vs 798/844, but RR is reported as 0.76; “Transfer to intensive care unit” is 111/831 vs 115/844, but RR is reported as 0.83.  
   - Table S12: alanine transaminase >2×ULN is shown as 9 (1.4%) vs 71 (1.1%), which is internally impossible; the RR 1.29 suggests the placebo count may be 7, not 71.  
   **Needed revision:** audit all tables against the analysis output and correct every RR, CI, mean difference, denominator, and typographical error. Given these discrepancies, editors should ask for a statistical review of the tables before acceptance.

5. **Per-protocol and sensitivity populations are inconsistently defined.**  
   - The Methods state that the per-protocol population excluded participants who received study drug >5 minutes after cord clamping “as well as those who received open-label tranexamic acid” (Statistical analysis, p10, lines 296–298).  
   - The figure legend and SAP define the per-protocol population only as those receiving tranexamic acid/placebo within 5 minutes after cord clamping (Figure 1 legend, p13, lines 426–430; SAP Analysis populations, p87). Table S11 still includes open-label tranexamic acid use, confirming that open-label use was not excluded from the per-protocol population.  
   - Excluding open-label tranexamic acid is also a post-randomisation, bleeding-triggered exclusion and should not be interpreted as a conventional per-protocol causal analysis.  
   **Needed revision:** use one consistent definition throughout. Label the “without open-label tranexamic acid” analysis as post hoc/exploratory and avoid treating it as confirmatory.

6. **PAS diagnosis and PAS subgroup analyses need much clearer handling.**  
   - Manuscript Methods say two senior obstetricians reviewed surgical records and pathology reports “post hoc for all cases” to ensure PAS diagnostic accuracy (Participants, p7–8, lines 190–196). The protocol version history says only the 661 patients initially identified with PAS were re-reviewed, reducing confirmed PAS to 303/1694; this leaves unclear whether initial false negatives were assessed (protocol p53).  
   - PAS was a prespecified subgroup (Statistical analysis, p10, lines 299–300), but the defining classification was changed after the trial and in response to peer-review feedback.  
   - Discussion reports partial myometrial resection “160/311 [51.4%]” (p12, lines 375–377), but Tables S8/S10 do not show totals matching 311 or 160, suggesting an outdated PAS-related number.  
   **Needed revision:** explicitly describe the original PAS variable, the re-adjudication process, whether non-PAS cases were reviewed, and provide PAS subgroup results using both original and adjudicated definitions. Correct the inconsistent PAS surgical numbers.

7. **Subgroup and secondary analyses are over-interpreted relative to multiplicity and power.**  
   - The manuscript correctly states that no multiplicity adjustment was made (Statistical analysis, p10, lines 301–304), but Results state that “No significant variation was observed” across subgroups including antepartum haemorrhage and PAS (p11, lines 333–335). No interaction P values are reported, and absence of statistical significance is not evidence of homogeneous effects, particularly for PAS subgroups.  
   - Antepartum haemorrhage is explicitly post hoc (Statistical analysis, p10, lines 301–302), but Figure 2 legend refers to “prespecified subgroups” (p14, lines 431–434), which would be inaccurate if antepartum haemorrhage is included in that figure.  
   - Ref12 states subgroup analyses would examine primary and secondary outcomes within age/type/PAS subgroups; the manuscript reports primary-outcome subgroups only.  
   **Needed revision:** report interaction tests, clearly label post hoc subgroups, soften “no difference/no variation” language, and reconcile whether secondary-outcome subgroup analyses were prespecified but omitted.

8. **Safety conclusions are too strong for the data.**  
   - Abstract and Conclusions state tranexamic acid reduced PPH “without increasing serious adverse events” (Abstract, p5, lines 127–131). Table 3 shows only 4 serious adverse events in each group, with RR 1.01 and 95% CI 0.25 to 4.01. For thromboembolic events, the CI is also very wide.  
   - The trial excluded women with several thrombotic or medical risk factors (Table S2), limiting generalisability of safety findings. Laboratory safety outcomes in Table S12 have substantial missingness for several measures.  
   **Needed revision:** change wording to “no evidence of an increase in serious adverse events was observed” and explicitly state that the trial was underpowered to exclude clinically important increases in rare harms.

## 3. Minor points

1. **Baseline significance testing is unnecessary and potentially misleading in an RCT.** Table S8 reports P values for baseline characteristics. Prefer descriptive reporting and discussion of clinically relevant imbalances.

2. **The post hoc simulation-based power analysis should be removed or clearly labelled as descriptive.** The sample size calculation was based on a two-sample comparison of proportions (Sample size, p9, lines 268–276); the post hoc simulation power statement (p9, lines 276–279) adds little and could be misread as validating the observed result.

3. **Primary missing-data handling should be clarified.** Three placebo participants lacked postoperative haematocrit (Results, p11, lines 323–325). State whether red cell transfusion status was known for these women and whether the composite could have been classified from transfusion alone.

4. **Report CIs for NNTs.** NNTs are given for PPH, calculated blood loss, and transfusion (Results, p11, lines 329–332), but without uncertainty.

5. **Clarify “adjusted P-value” wording.** Table 2 footnote says “The adjusted P-value for postpartum haemorrhage was 0.0035.” If this is simply the model P value assessed against an O’Brien–Fleming-adjusted threshold, say so; if it is adjusted, describe the adjustment.

6. **Calculated blood loss in transfused participants is underspecified.** The primary outcome definition explains calculated blood loss if transfusion was not required (Outcomes, p8–9, lines 242–248), while Table 2 separately reports calculated blood loss ≥1000 mL and transfusion. Clarify how calculated blood loss was handled for participants transfused before the postoperative haematocrit sample.

7. **Adverse events within 24 hours appear incompletely reported.** SAP timing says adverse events were assessed in the operating room and within 24 hours after delivery (SAP p86), but Table 3 reports only “in the operating room” for mild adverse events.

8. **Typographical/reporting errors should be corrected.** Examples include “confidencial” in the SAP, “requring” in Table 3, “Blingding” and “cancealment” in the CONSORT checklist, and “mean (IQR)” in Table S8 for variables displayed as medians.

## 4. Anything you verified that checked out

1. **Primary outcome definition is consistent with the cited TRAAP2 approach.** Ref7 defines postpartum haemorrhage as calculated estimated blood loss >1000 mL or red cell transfusion within 2 days after delivery, matching the manuscript’s primary outcome with the minor threshold wording difference of ≥1000 mL.

2. **The sample-size assumptions in the manuscript match the protocol/SAP.** The manuscript’s assumed placebo event rate of 33%, target 20% relative reduction to 26.4%, 80% power, and 1680 total target are consistent with ref12 and the bound protocol/SAP.

3. **Use of an O’Brien–Fleming alpha-spending approach was prespecified.** The manuscript’s final significance threshold P<0.048 is consistent with the protocol/SAP statement that one interim analysis would use an O’Brien–Fleming boundary.

4. **The intervention timing and dose are consistent across manuscript and protocol.** The manuscript’s 1 g tranexamic acid/placebo diluted to 50 mL and infused over 10 minutes within 5 minutes after cord clamping matches ref12 and the bound protocol.

5. **The manuscript’s statement about the Pacheco et al trial infection signal is supported by ref8.** Ref8 reports postpartum infection of 3.2% vs 2.5% with tranexamic acid vs placebo, consistent with the Discussion comparison.

## 5. Editorial recommendation

**Major revision.** The primary estimate suggests a potentially important reduction in the trial’s composite PPH endpoint, and the design is broadly appropriate for the clinical question. However, the current submission has major reporting and statistical issues: unclear pre-specification chronology, post hoc PAS reclassification, incomplete adjustment/reporting relative to stratified randomisation, inconsistent per-protocol definitions, overstatement of safety, and multiple numerical inconsistencies in key tables. These issues are fixable if the authors provide a transparent version history, corrected tables, prespecified and sensitivity analyses, and appropriately tempered conclusions, but the manuscript is not ready for acceptance in its current form.

## 6. What I could not assess

1. I could not verify the randomisation sequence, allocation concealment implementation, or whether analysis changes occurred before unblinding because no raw data, randomisation logs, DSMB minutes, or analysis code were provided.

2. I could not assess model convergence, centre-level event distributions, or whether the reported mixed-effects models were implemented exactly as described.

3. I could not independently reproduce any estimates or confidence intervals without participant-level data and code.

4. I could not check claims that depend on missing references 5 and 16, because those PDFs were not provided.

5. I could not determine whether the ClinicalTrials.gov record contained earlier prespecified outcomes or analysis details, because internet access was unavailable.

===== TOKENS =====
api_calls=23  input=1739625  output=13660  (reasoning=9451)  total=1753285

===== END (2026-06-03T21:49:32) =====